FDA Approved NDA for KOSELUGO™ (selumetinib)
Andy Henton2020-10-22T10:16:40-04:00October 22nd, 2020|Categories: Featured, Industry News|Tags: AstraZeneca, FDA, KOSELUGO, NF1, research, RWE, selumetinib|
Recently the FDA approved AstraZeneca’s KOSELUGO™ (selumetinib) for treatment of pediatric patients two years of age and older with neurofibromatosis [...]
Receive essential insights, resources and content direct to your inbox!
Hit subscribe to stay informed!
Advertisement
Latest News
Featured Webinars
Navigating the Clinical Outcomes Maze: An Overview of Clinical Outcomes Assessments and Why Training Matters
Tuesday, December 5, 2023
Sponsor: ICON
EU HTA Joint Clinical Assessments: Navigating Potential Challenges Ahead of 2025
Friday, November 10, 2023
Sponsor: OpenHealth
Cell & Gene Therapies – Beginning with the End in Mind
Thursday, November 2, 2023
Sponsor: Magnolia Market Access
Categories
Artificial Intelligence
Careers
Clinical Trials
Cost Effectiveness
Data Analytics & Syndicated Reports
Healthcare Financing
Health Databases
Health Equity
Health Policy
Health Tech Assessment
Integrated Evidence Assessment & Planning
Market Access
Medical Affairs
Patient Outcomes & Engagement
Pricing & Reimbursement
Real World Data
Real World Evidence
Value Assessment
Value Communication